(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -10.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Cytomx Therapeutics's revenue in 2026 is $76,201,000.On average, 11 Wall Street analysts forecast CTMX's revenue for 2026 to be $4,594,361,287, with the lowest CTMX revenue forecast at $667,132,029, and the highest CTMX revenue forecast at $14,295,686,328. On average, 10 Wall Street analysts forecast CTMX's revenue for 2027 to be $5,845,063,654, with the lowest CTMX revenue forecast at $333,566,014, and the highest CTMX revenue forecast at $15,135,557,900.
In 2028, CTMX is forecast to generate $10,010,894,725 in revenue, with the lowest revenue forecast at $3,335,660,143 and the highest revenue forecast at $15,135,557,900.